The Janssen Pharmaceutical Companies of Johnson & Johnson reported updated results from Legend Biotech Inc.’s LEGEND-2 phase I/II open-label study, which evaluated the investigational chimeric antigen receptor T-cell therapy LCAR-B38M in the treatment of patients with advanced relapsed or refractory multiple myeloma.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe